Opinion

Video

Clinical Trials Investigating Rectal Spacers in Prostate Cancer

Author(s):

Brian Mazzarella, MD,Jeffrey T. Schiff, MD, MPH

A detailed overview of clinical trials and ongoing research in prostate cancer investigating rectal spacers.

Current Time 0:00
Duration 4:48
Loaded: 0%
Stream Type LIVE
Remaining Time 4:48
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
    Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
    Betty Wang, MD, discusses studies from the 2025 EAU meeting
    Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
    Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
    Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
    Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
    Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
    Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
    Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
    Dr Louise Kostos answers a question during a Zoom video interview
    Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
    Dr Louise Kostos answers a question during a Zoom video interview
    An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
    Rana McKay, MD, on the role of radium-223 in the modern era
    Rana McKay, MD, on the role of radium-223 in the modern era
    Dr Louise Kostos answers a question during a Zoom video interview
    Dr Louise Kostos discusses PSA kinetics in mHSPC
    Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
    The importance of PSADT in high-risk, biochemically recurrent prostate cancer
    Related Content
    Urologists perform first remote robot-assisted HIFU for prostate cancer
    April 17th 2025

    Urologists perform first remote robot-assisted HIFU for prostate cancer

    Hannah Clarke
    “We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Study underway to assess 3-fraction SBRT regimen in prostate cancer
    April 14th 2025

    Study underway to assess 3-fraction SBRT regimen in prostate cancer

    Hannah Clarke
    "The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.
    Dr. Schwen on focal therapies for prostate cancer
    January 11th 2024

    Dr. Schwen on focal therapies for prostate cancer

    Cleveland Clinic
    Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
    Genetic test can predict risk of toxicity following radiation for prostate cancer
    April 7th 2025

    Genetic test can predict risk of toxicity following radiation for prostate cancer

    Hannah Clarke
    "This finding reinforces PROSTOX ultra as a true measure of the biological response to radiation, independent of treatment era or technique that can identify the safest course of treatment to avoid toxicity," says Amar U. Kishan, MD.
    What urologists can expect in Q2 of 2025
    April 7th 2025

    What urologists can expect in Q2 of 2025

    Hannah Clarke Benjamin P. Saylor
    A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
    © 2025 MJH Life Sciences

    All rights reserved.